World Pain Relieving Drug Market 2012-2022Visiongain
August 8, 2012
235 Pages - SKU: VSG4881895
6.8.2 Nucynta ER Sales Forecast, 2012-2022
The global sales for Nucynta ER in 2011 were estimated at $51m. Nucynta ER was launched in 2011 and will achieve strong sales throughout the forecast period. Visiongain believes it will reach blockbuster status by 2017, with a CAGR of 65.4% from 2011-2017 (Table 6.11 and Figure 6.10). Nucynta ER’s success will be driven by its efficacy in both neuropathic and nociceptive pain conditions. As a result, it is expected to be prescribed for conditions involving both pain types, such as chronic lower back pain. Its opioid-sparing effects and reduced potential for abuse will also be key clinical advantages for Nucynta ER in neuropathic pain conditions that require long-term management. In addition the experience of Johnson and Johnson within the US pain market will increase sales in the US.
American Council for Headache Education
Centocor Ortho Biotech
CK Life Sciences
Dr. Reddy's Laboratories
European Medicines Agency (EMA)
Food and Drug Administration (FDA)
Human Genome Sciences
International Association for the Study of Pain (IASP)
Johns Hopkins University
Johnson and Johnson (J&J)
Merck & Co.
Mitsubishi Tanabe Pharma
National Health Service (NHS)
National Institute for Health and Clinical Excellence (NICE)
Procter & Gamble
Teva Pharmaceutical Industries
The Arthritis Foundation
The International Diabetes Federation (IDF)
The Neuropathy Association
The World Health Organization (WHO)
University of Queensland
US Census Bureau
US Society for Neuroscience
Valeant Pharmaceuticals International
Wyeth (now part of Pfizer)
More Global CNS/Neurology reports
Global Deep Brain Stimulator Market 2012-2016 by Infiniti Research Limited
Global Deep Brain Stimulator Market 2012-2016 TechNavio's analysts forecast the Global Deep Brain Stimulator market to grow at a CAGR of 16.99 percent over ...
Anorexia Nervosa Global Clinical Trials Review, H1, 2013 by GlobalData
Anorexia Nervosa Global Clinical Trials Review, H1, 2013SummaryGlobalData's clinical trial report, “Anorexia Nervosa Global Clinical Trials Review, H1, 2013 provides data on the Anorexia Nervosa ...
Dyslexia Global Clinical Trials Review, H1, 2013 by GlobalData
Dyslexia Global Clinical Trials Review, H1, 2013SummaryGlobalData's clinical trial report, “Dyslexia Global Clinical Trials Review, H1, 2013 provides data on the Dyslexia clinical trial scenario. ...
Disease and Therapy Review: Generalized Anxiety Disorder (GAD) by Timely Data Resources, Inc.See all reports like this >>
The Generalized Anxiety Disorder (GAD) Disease and Therapy Review provides an overview of the disease and related conditions, with prevalence numbers and percentages for major ...
We can help you find what you need. Call us or write us:
Need help in your search?
- Diseases & Conditions
- Manufacturing, Packaging & Detailing
- Research & Development
- Drug Discovery
- Therapeutic Area